Scalper1 News
Shares of biotech Aerie Pharmaceuticals (AERI) vaulted as much as 85% Thursday and got a passel of price target increases after the company announced late Wednesday that its glaucoma drug had succeeded in a late-stage clinical trial. Aerie said that its eye drop Rhopressa had succeeded in lowering intra-ocular pressure in sufferers from glaucoma and ocular hypertension. Its goal was to show that a once-daily dose of Rhopressa was non-inferior to Scalper1 News
Scalper1 News